Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study

The most important complications of Philadelphianegagive (non BCR-ABL) myeloproliferative neoplasms (MPNs) are vascular events. Our aim was to evaluate the effects of single nucleotide polymorphisms (SNPs), platelet glycoproteins (GPs) (Ia/IIa, Ibα, IIb/IIIa and VI), von Willebrand factor (vWF), coa...

Full description

Bibliographic Details
Main Authors: Dambrauskienė R, Gerbutavičius R, Ugenskienė R, Jankauskaitė R, Savukaitytė A, Šimoliūnienė R, Rudžianskienė M, Gerbutavičienė R, Juozaitytė E
Format: Article
Language:English
Published: Sciendo 2017-06-01
Series:Balkan Journal of Medical Genetics
Subjects:
Online Access:https://doi.org/10.1515/bjmg-2017-0005
id doaj-74fbf3995b1d4649a2e774892735ad72
record_format Article
spelling doaj-74fbf3995b1d4649a2e774892735ad722021-09-05T20:42:32ZengSciendoBalkan Journal of Medical Genetics1311-01602017-06-01201354210.1515/bjmg-2017-0005bjmg-2017-0005Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot studyDambrauskienė R0Gerbutavičius R1Ugenskienė R2Jankauskaitė R3Savukaitytė A4Šimoliūnienė R5Rudžianskienė M6Gerbutavičienė R7Juozaitytė E8Department of Oncology and Hematology, Institute of Oncology, Lithuanian University of Health Sciences, Kaunas, LithuaniaDepartment of Oncology and Hematology, Institute of Oncology, Lithuanian University of Health Sciences, Kaunas, LithuaniaLithuanian University of Health Sciences, Institute of Oncology, Oncology Research Laboratory, Kaunas, LithuaniaLithuanian University of Health Sciences, Institute of Oncology, Oncology Research Laboratory, Kaunas, LithuaniaLithuanian University of Health Sciences, Institute of Oncology, Oncology Research Laboratory, Kaunas, LithuaniaDepartment of Physics, Mathematics and Biophysics, Lithuanian University of Health Sciences, Kaunas, LithuaniaDepartment of Oncology and Hematology, Institute of Oncology, Lithuanian University of Health Sciences, Kaunas, LithuaniaDepartment of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Lithuanian University of Health Sciences, Kaunas, LithuaniaDepartment of Oncology and Hematology, Institute of Oncology, Lithuanian University of Health Sciences, Kaunas, LithuaniaThe most important complications of Philadelphianegagive (non BCR-ABL) myeloproliferative neoplasms (MPNs) are vascular events. Our aim was to evaluate the effects of single nucleotide polymorphisms (SNPs), platelet glycoproteins (GPs) (Ia/IIa, Ibα, IIb/IIIa and VI), von Willebrand factor (vWF), coagulation factor VII (FVII), β-fibrinogen, and the risk of thrombosis in patients with non BCR-ABL MPNs at the Lithuanian University of Health Sciences. Kaunas, Lithuania. Genotyping was done for 108 patients. The TT genotype of the GP Ia/IIa c.807C>T polymorphism was more frequently found in the group of MPN patients with arterial thrombosis compared to MPN patients who were thrombosis-free [26.5 vs. 11.5%, p = 0.049; odds ratio (OR) 2.68; 95% confidence interval (95% CI) 1.01-7.38]. The CT genotype of the β-fibrinogen c.-148C>T polymorphism occurred more frequently in MPN patients with arterial, and total thrombosis compared to the wild or homozygous genotype (57.7 vs. 40.0 vs. 12.5%; p = 0.027), (64.7 vs. 44.4 vs. 25%; p = 0.032), respectively. The carrier state for the c.-323P10 variant of FVII SNP (summation of P10/10 and P0/10) was more frequent in MPN patients with thrombosis compared to the wild-type genotype carriers (71.4 vs. 43.4%; p = 0.049; OR 3.26; 95% CI 1.01-11.31). The coexistence of heterozygous β-fibrinogen c.-148C>T and FVII c.-323P0/10 SNP, increased the risk of arterial thrombosis (21.1 vs. 3.7%, p = 0.008; OR 6.93; 95% CI 1.38-34.80). The TT genotype of GP Ia/IIa c.807C>T, the CT genotype of β-fibrinogen c.-148C>T and FVII c.-323P0/10 SNP could be associated with risk of thrombosis in MPN patients.https://doi.org/10.1515/bjmg-2017-0005genetic polymorphismmyeloproliferative neoplasiathrombosis
collection DOAJ
language English
format Article
sources DOAJ
author Dambrauskienė R
Gerbutavičius R
Ugenskienė R
Jankauskaitė R
Savukaitytė A
Šimoliūnienė R
Rudžianskienė M
Gerbutavičienė R
Juozaitytė E
spellingShingle Dambrauskienė R
Gerbutavičius R
Ugenskienė R
Jankauskaitė R
Savukaitytė A
Šimoliūnienė R
Rudžianskienė M
Gerbutavičienė R
Juozaitytė E
Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
Balkan Journal of Medical Genetics
genetic polymorphism
myeloproliferative neoplasia
thrombosis
author_facet Dambrauskienė R
Gerbutavičius R
Ugenskienė R
Jankauskaitė R
Savukaitytė A
Šimoliūnienė R
Rudžianskienė M
Gerbutavičienė R
Juozaitytė E
author_sort Dambrauskienė R
title Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
title_short Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
title_full Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
title_fullStr Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
title_full_unstemmed Genetic polymorphisms of hemostatic factors and thrombotic risk in non BCR-ABL myeloproliferative neoplasms: A pilot study
title_sort genetic polymorphisms of hemostatic factors and thrombotic risk in non bcr-abl myeloproliferative neoplasms: a pilot study
publisher Sciendo
series Balkan Journal of Medical Genetics
issn 1311-0160
publishDate 2017-06-01
description The most important complications of Philadelphianegagive (non BCR-ABL) myeloproliferative neoplasms (MPNs) are vascular events. Our aim was to evaluate the effects of single nucleotide polymorphisms (SNPs), platelet glycoproteins (GPs) (Ia/IIa, Ibα, IIb/IIIa and VI), von Willebrand factor (vWF), coagulation factor VII (FVII), β-fibrinogen, and the risk of thrombosis in patients with non BCR-ABL MPNs at the Lithuanian University of Health Sciences. Kaunas, Lithuania. Genotyping was done for 108 patients. The TT genotype of the GP Ia/IIa c.807C>T polymorphism was more frequently found in the group of MPN patients with arterial thrombosis compared to MPN patients who were thrombosis-free [26.5 vs. 11.5%, p = 0.049; odds ratio (OR) 2.68; 95% confidence interval (95% CI) 1.01-7.38]. The CT genotype of the β-fibrinogen c.-148C>T polymorphism occurred more frequently in MPN patients with arterial, and total thrombosis compared to the wild or homozygous genotype (57.7 vs. 40.0 vs. 12.5%; p = 0.027), (64.7 vs. 44.4 vs. 25%; p = 0.032), respectively. The carrier state for the c.-323P10 variant of FVII SNP (summation of P10/10 and P0/10) was more frequent in MPN patients with thrombosis compared to the wild-type genotype carriers (71.4 vs. 43.4%; p = 0.049; OR 3.26; 95% CI 1.01-11.31). The coexistence of heterozygous β-fibrinogen c.-148C>T and FVII c.-323P0/10 SNP, increased the risk of arterial thrombosis (21.1 vs. 3.7%, p = 0.008; OR 6.93; 95% CI 1.38-34.80). The TT genotype of GP Ia/IIa c.807C>T, the CT genotype of β-fibrinogen c.-148C>T and FVII c.-323P0/10 SNP could be associated with risk of thrombosis in MPN patients.
topic genetic polymorphism
myeloproliferative neoplasia
thrombosis
url https://doi.org/10.1515/bjmg-2017-0005
work_keys_str_mv AT dambrauskiener geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT gerbutaviciusr geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT ugenskiener geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT jankauskaiter geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT savukaitytea geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT simoliuniener geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT rudzianskienem geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT gerbutaviciener geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
AT juozaitytee geneticpolymorphismsofhemostaticfactorsandthromboticriskinnonbcrablmyeloproliferativeneoplasmsapilotstudy
_version_ 1717785535112544256